Afamelanotide

Chemical compound Pharmaceutical compound Afamelanotide, sold under the brand name Scenesse, is a medication used to prevent phototoxicity and to reduce pain from light exposure for people with erythropoietic protoporphyria, a rare form of genetic sun sensitivity. Afamelanotide is a melanocortin 1 receptor (MC1 receptor) agonist and a synthetic peptide and analogue of α-melanocyte stimulating hormone. It is administered as subcutaneous implant. Medical uses In the European Union, afamelanotide is indicated for the prevention of phototoxicity in adults with erythropoietic protoporphyria. In the United States, afamelanotide is indicated for increasing pain-free light exposure in adults with a history of reactions to light (phototoxicity) from erythropoietic protoporphyria. Adverse effects The most common reported adverse effects were nausea (19%), headache (20%), and implant site reactions (21%). Uncommon but potentially serious hypersensitivity reactions including anaphylaxis were also reported. Afamelanotide was also found to sometimes induce darkening of certain pre-existing skin conditions, so regular full body skin examinations every 6 months is often recommended. Other common